http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011117894-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b35511c6fd2b793207a8972be0f47425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b620a3a63063d57b9d52c7952227341 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate | 2011-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c14b4ff30c0e8c775ac3afcd898a43f |
| publicationDate | 2011-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2011117894-A1 |
| titleOfInvention | Pharmaceutical technology of pharmaceutical composition in novel/sequential drug delivery system containing nitric oxide donor |
| abstract | The present invention relates to pharmaceutical technology of pharmaceutical composition in Novel/Sequential Drug Delivery System containing Nitric Oxide Donors, more particularly, selective Endothelial Nitric Oxide Synthase Enhancers and in synergistic combination with Nitic Oxide Scavengers, Lipid Lowering Agents, as nanonized particles, from amongst, HMG Co-A Reductase Inhibitors, Ezetimibe and Fibrates and additionally other pharmaceutical substances that prevent/treat Atherosclerosis and provide round-the-clock cardio-protection. Following are the specific objectives of the present invention: a) Provide optimum benefits of Nitric Oxide and make it devoid of its adverse effects, through our unique technology and thus make it relatively safe for long-term usage. b) Provide synergistic combination of Lipid Lowering Agents with Nitric Oxide to achieve the dual objectives of a) Vasodilatation and b) Improve Dyslipidemia. c) Improve Quality of Life in patients with Ischemic Heart Disease. |
| priorityDate | 2010-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.